Gene-expression profiling to predict responsiveness to immunotherapy - PubMed (original) (raw)
Review
. 2017 Mar;24(3):134-140.
doi: 10.1038/cgt.2016.63. Epub 2016 Nov 11.
Affiliations
- PMID: 27834354
- PMCID: PMC5386795
- DOI: 10.1038/cgt.2016.63
Review
Gene-expression profiling to predict responsiveness to immunotherapy
N B Jamieson et al. Cancer Gene Ther. 2017 Mar.
Abstract
Recent clinical successes with immunotherapy have resulted in expanding indications for cancer therapy. To enhance antitumor immune responses, and to better choose specific strategies matched to patient and tumor characteristics, genomic-driven precision immunotherapy will be necessary. Herein, we explore the role that tumor gene-expression profiling (GEP) may have in the prediction of an immunotherapeutic response. Genetic markers associated with response to immunotherapy are addressed as they pertain to the tumor genomic landscape, the extent of DNA damage, tumor mutational load and tumor-specific neoantigens. Furthermore, genetic markers associated with resistance to checkpoint blockade and relapse are reviewed. Finally, the utility of GEP to identify new tumor types for immunotherapy and implications for combinatorial strategies are summarized.
Conflict of interest statement
Conflict of interest
The authors declare no conflict of interest
Similar articles
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. Thomas R, et al. Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. eCollection 2018. Front Immunol. 2018. PMID: 29770138 Free PMC article. Review. - Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
Mandal R, Chan TA. Mandal R, et al. Cancer Discov. 2016 Jul;6(7):703-13. doi: 10.1158/2159-8290.CD-16-0146. Epub 2016 Apr 22. Cancer Discov. 2016. PMID: 27107038 Free PMC article. Review. - Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, El-Dakdouki Y, Champiat S, Aoufouchi S, Leary A, Marabelle A, Malka D, Chaput N, Kannouche PL. Nebot-Bral L, et al. Eur J Cancer. 2017 Oct;84:290-303. doi: 10.1016/j.ejca.2017.07.026. Epub 2017 Aug 29. Eur J Cancer. 2017. PMID: 28846956 Review. - Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.
Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria JC, Postel-Vinay S. Chabanon RM, et al. Clin Cancer Res. 2016 Sep 1;22(17):4309-21. doi: 10.1158/1078-0432.CCR-16-0903. Epub 2016 Jul 7. Clin Cancer Res. 2016. PMID: 27390348 Review. - Tackling Resistance to Cancer Immunotherapy: What Do We Know?
Gondhowiardjo SA, Handoko, Jayalie VF, Apriantoni R, Barata AR, Senoaji F, Utami IJW, Maubere F, Nuryadi E, Giselvania A. Gondhowiardjo SA, et al. Molecules. 2020 Sep 8;25(18):4096. doi: 10.3390/molecules25184096. Molecules. 2020. PMID: 32911646 Free PMC article. Review.
Cited by
- Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers.
Meci A, Goyal N, Slonimsky G. Meci A, et al. Cancers (Basel). 2024 Feb 7;16(4):703. doi: 10.3390/cancers16040703. Cancers (Basel). 2024. PMID: 38398094 Free PMC article. Review. - Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
Dong X, Liu T, Li Z, Zhai Y. Dong X, et al. Aging (Albany NY). 2023 Jul 26;15(14):7237-7257. doi: 10.18632/aging.204904. Epub 2023 Jul 26. Aging (Albany NY). 2023. PMID: 37498296 Free PMC article. - Immunotherapy in malignant peritoneal mesothelioma (Review).
Alaklabi S, Roy AM, Skitzki JJ, Iyer R. Alaklabi S, et al. Mol Clin Oncol. 2023 Feb 22;18(4):31. doi: 10.3892/mco.2023.2627. eCollection 2023 Apr. Mol Clin Oncol. 2023. PMID: 36908980 Free PMC article. Review. - PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors.
Gabryś HS, Basler L, Burgermeister S, Hogan S, Ahmadsei M, Pavic M, Bogowicz M, Vuong D, Tanadini-Lang S, Förster R, Kudura K, Huellner M, Dummer R, Levesque MP, Guckenberger M. Gabryś HS, et al. Front Oncol. 2022 Nov 24;12:977822. doi: 10.3389/fonc.2022.977822. eCollection 2022. Front Oncol. 2022. PMID: 36505821 Free PMC article. - Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab.
Monastirioti A, Papadaki C, Kalapanida D, Rounis K, Michaelidou K, Papadaki MA, Mavroudis D, Agelaki S. Monastirioti A, et al. Cancers (Basel). 2022 Sep 28;14(19):4739. doi: 10.3390/cancers14194739. Cancers (Basel). 2022. PMID: 36230658 Free PMC article.
References
- Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013;31(15):1806–1814. - PubMed
- Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources